RET and medullary thyroid gland carcinoma: The MGFT department is also accredited with ISO 15189 for the genetic test of RET proto-oncogene and since 2002 has performed more than 500 tests in patients with clinical MEN2 manifestations i.e. medullary thyroid carcinoma (MTC), pheochromocytoma, hyperparathyroidism and cutaneous lichen amyloidosis (Fig. 4).